Efficacy of adjuvant capecitabine in triple-negative breast cancer with residual disease after neoadjuvant therapy: a real-world study
Adjuvant capecitabine therapy significantly improved the prognosis of patients with TNBC who had residual disease after NAT, and the improvements in the outcomes were significant in patients with HER2-low expression and stage III disease. Other effective treatment methods should be explored for patients with HER2-0 expression or stage II disease.
Authors
- Xiuchun Chen (ORCID: https://orcid.org/0000-0002-7134-7170)
- Mingda Zhu (ORCID: https://orcid.org/0000-0003-1990-8943)
- Jingyang Zhang (ORCID: https://orcid.org/0000-0002-4347-9416)
- Youzhao Ma (ORCID: https://orcid.org/0000-0002-6056-5703)
- Yangyang Hou
- Zhenzhen Liu (ORCID: https://orcid.org/0000-0002-3878-1258)
- Dechuang Jiao (ORCID: https://orcid.org/0009-0003-7441-9103)
Institutions
- Fudan University (CN)
- Pudong Medical Center (CN)
- Henan Cancer Hospital (CN)
Publication Details
- Journal
- The Breast
- Published
- 2025-04-15
- DOI
- https://doi.org/10.1016/j.breast.2025.104477
- Citations
- 3
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.81